Contraindication
Hypersensitivity to desidustat or any excipients.
For healthcare professionals and patients
Safety and prescribing information
Approved for the treatment of anaemia associated with chronic kidney disease in adult patients on dialysis and not on dialysis.
Prescription-only medicine · Use under medical supervision.
Rx Prescription-only medicinePI Prescribing Information · Version 4.0
1
Before use
Food window
No food one hour before and two hours after the dose.
Rx
Use only as prescribed
Do not use for a condition for which it was not prescribed.
No
Do not share
Do not share the medicine with others.
2
Trial safety by population
ND
Non-dialysis · DREAM-ND
Desidustat vs darbepoetin alfa
85.2% vs 85.7%Treatment-emergent adverse events- 251/588 vs 252/587
- Serious adverse events: 10.7% vs 11.1%
- 24-week open-label active-controlled trial
Dialysis-dependent · DREAM-D
Desidustat vs epoetin alfa
86.5% vs 88.0%Treatment-emergent adverse events- 339/392 vs 345/392
- Serious adverse events: 13.8% vs 14.0%
- 24-week open-label active-controlled trial
i
Safety data are study-specific. Do not combine populations or reporting thresholds.
2A
Related safety evidence
Observational real-world evidence
Gulati et al. (2026)
No new safety signals were reported; mild constipation and throat discomfort were described. Retrospective limitations apply.
Explore real-world tolerabilityCN
Other trial evidence
China Phase III (NDD-CKD)
Placebo-controlled safety evidence should be read using its own timeframe, comparator and denominators.
View China Phase III context3
Special populations
Preg
Pregnancy
Safety has not been established. Use only if potential benefit justifies potential risk.
Nurs
Nursing mothers
Desidustat should not be used in nursing mothers according to the PI.
WCP
Women of childbearing potential
Use appropriate contraception during treatment.
Paed
Paediatric use
Safety and efficacy have not been established.
Geri
Geriatric use
Use with caution considering comorbidity and concomitant medicines.
4
Drug interactions
CYP
CYP-mediated interactions
Available in-vitro data suggest minimal potential for clinically mediated drug–drug interactions based on CYP pathways.
OAT3
Transporter information
Desidustat is a substrate of OAT3 and may be affected by OAT3 inhibitors. Refer to the PI for the full interaction context.
Open PIi
Do not simplify the available evidence to “no drug interactions.”
5
Driving, overdose and storage
Driving and using machines
The PI states no or negligible influence on ability to drive and use machines.
Overdose
Provide supportive care and monitor vital signs as needed.
Storage
Store below 30°C, protect from moisture and keep out of reach of children.
6
Adverse-event reporting
Toll-free number
1800 419 1141Report suspected adverse drug reactions.
Drug-safety email
drugsafety@zyduslife.comZydus Lifesciences drug safety.
Reporting information
www.zyduslife.comContact a healthcare professional for symptoms after use.
7
Full PI and related links
i
This page is a summary. Always refer to the full prescribing information before prescribing.